Kindred Biosciences announces plans to price public offering of stock

Leerink, BMO and Guggenheim assist; deal funds research, development

By Devika Patel

Knoxville, Tenn., March 18 - Kindred Biosciences, Inc. will price a public sale of its common stock with a 30-day greenshoe, according to a Form S-1 and 8-K filed Tuesday with the Securities and Exchange Commission.

Leerink Partners LLC will be the lead bookrunning manager and BMO Capital Markets Corp. and Guggenheim Securities, LLC will be joint bookrunning managers.

Proceeds will be used for research and development of product candidates, potential acquisitions, general corporate and working capital purposes.

The biopharmaceutical company is based in Burlingame, Calif.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.